

Heart Failure 2012

CONGRESS ORGANISED BY THE HEART FAILURE ASSOCIATION OF THE ESC TOGETHER WITH THE ANNUAL CONGRESS OF THE EUROPEAN SECTION OF THE INTERNATIONAL SOCIETY FOR HEART RESEARCH AND THE ESC WORKING GROUP ON MYOCARDIAL FUNCTION

BELGRADE
SERBIA
19-22 MAY



www.escardio.org/HFA

CARDIOLOGISTS - INTERNISTS - GENERAL PRACTITIONERS - PHYSICIANS - BASIC SCIENTISTS
EPIDEMIOLOGISTS - NURSES - INDUSTRY AFFILIATES - HEALTH CARE PROVIDERS

ADVANCE PROGRAMME

Myocardial Function
ESC Working Group



ISHR
International Society for Heart Research
European Section



HEART FAILURE
ASSOCIATION
OF THE ESC

EUROPEAN
SOCIETY OF
CARDIOLOGY®

Important Dates

14 January 2012

Deadline for
abstract submission

19 March 2012

Early-bird registration deadline

16 April 2012

Advance registration deadline

Let us also help you find
accommodation with our
online hotel booking service



Follow us on



www.escardio.org/HFA

or contact us at:
HFsecretariat@escardio.org



Belgrade

the city of the future in Southern Europe

Co-organising Committees

Board of the Heart Failure Association (HFA) of the ESC

P. Ponikowski FESC (Wrocław, PL)	President
S.D. Anker FESC (Berlin, DE)	President-Elect
J. McMurray FESC (Glasgow, GB)	Immediate Past-President
G. Filippatos FESC (Athens, GR)	Chairperson Clinical Section
B. Pieske FESC (Graz, AT)	Chairperson Basic Sciences Section
A. Maggioni FESC (Florence, IT)	Secretary
F. Zannad FESC (Nancy, FR)	Treasurer
A. Hoes (Utrecht, NL)	L. Neyses (Manchester, GB)
I. Ekman NFESC (Gothenburg, SE)	Z. Papp FESC (Debrecen, HU)
T. McDonagh FESC (London, GB)	J. Riley NFESC (London, GB)
C. Maack (Hamburg, DE)	F. Ruschitzka FESC (Zurich, CH)
V. Mareev (Moscow, RU)	P. Seferovic FESC (Belgrade, RS)
A. Mebazaa FESC (Paris, FR)	

Ex-officio

D. van Veldhuisen FESC (Groningen, NL), Editor in Chief of the European Journal of Heart Failure

Sui Generi

K. Dickstein FESC (Stavanger, NO), G. Hasenfuss FESC (Göttingen, DE), A. Shah FESC (London, GB)

Council of the International Society for Heart Research (ISHR)

- European Section

T. Eschenhagen FESC (Hamburg, DE)	President
S. Harding FESC (London, GB)	Past-President
P. Ferdinandy (Szeged, HU)	President-Elect

ESC Working Group on Myocardial Function

D. Hilfiker-Kleiner FESC (Hannover, DE)	Chairperson
J. Bauersachs FESC (Hannover, DE)	Vice-Chairperson & Treasurer
J.-L. Balligand FESC (Brussels, BE)	Past-Chairperson

Scientific Programme Committee

The HFA Board members are part of the Scientific Committee

P. Seferovic FESC (Belgrade, RS)	Scientific Chairperson
P. Ponikowski FESC (Wrocław, PL)	President HFA of the ESC
S.D. Anker FESC (Berlin, DE)	President-Elect HFA of the ESC
Z. Papp FESC (Debrecen, HU)	HFA Basic Sciences Representative
J. Riley NFESC (London, GB)	HFA Nurse Representative
I. Ekman NFESC (Gothenburg, SE)	HFA Nurse Representative
T. Eschenhagen FESC (Hamburg, DE)	President ISHR European Section
D. Hilfiker-Kleiner FESC (Hannover, DE)	Chairperson ESC WG on Myocardial Function

Local Committee

N. Cemerlic Adic FESC (Novi Sad, RS)	D. Milicic FESC (Zagreb, HR)
M. Deljanin Ilic FESC (Nis, RS)	V. Mitrovic FESC (Bad Nauheim, DE)
D. Gaita FESC (Timisoara, RO)	A.N. Neskovic FESC (Belgrade, RS)
V. Kanjuh (Belgrade, RS)	S. Pavlovic FESC (Belgrade, RS)
M. Lainscak FESC (Golnik, SI)	A.D. Ristic FESC (Belgrade, RS)
R. Maksimovic (Belgrade, RS)	G. Stankovic FESC (Belgrade, RS)



Invitation

Dear friends and colleagues,

It is our pleasure to announce that the Heart Failure Congress 2012, which will be held in Belgrade, Serbia, 19-22 May, is organised not only by the Heart Failure Association of the European Society of Cardiology (HFA of the ESC) but also in conjunction with the European Section of the International Society for Heart Research (ES-ISHR) and the ESC Working Group on Myocardial Function. The aim of our joint Scientific Committee is to create an exciting forum for both clinicians and scientists to present, hear, exchange, and discuss the most up-to-date research and clinical findings in heart failure.

The programme has been carefully planned to provide state-of-the-art information about all aspects of heart failure - from basic science, through diagnostic strategies (including imaging and biomarkers), pharmacological and device therapy, disease monitoring (both biochemical and technological) and organisation of care (with special focus on the role of nurses, pharmacists and remote monitoring).

Integration of pharmacology and technology in the era of personalised heart failure management will be the overarching theme of the programme (including the management of co-morbidities, risk models, decision support systems and cell therapy), with the interpretation and application of the latest clinical trial results given centre stage. Based on delegate feedback from previous meetings, we have ensured that these topics will be covered in a variety of formats (expert lectures in plenary sessions, interactive educational sessions with case presentations, debates and original scientific contributions) by colleagues from many different countries. Participation of young cardiologists will be stimulated and supported through the Young Investigator Award sessions for basic and clinical research and International Heart Failure Societies' joint sessions.

For those working clinically, our main objective is to provide the knowledge required for your every day practice, including the use of devices and technologies (ICD, CRT, LVADs). Our faculty will provide a practical and international perspective, incorporating the latest ESC and brand new Heart Failure guidelines. For those whose principal concern is in research, sessions dedicated to the advances in the field of biomarkers, bio-imaging, and cell therapy will be of special interest.

Belgrade is one of the most exciting and rapidly developing European capitals, famous for its natural beauty, cultural events and hospitality. It will delight you with its two rivers, beautiful lake, many monuments, parks, archaeological sites and charming local restaurants.

Add this to the opportunity to network with your colleagues and friends in a welcoming environment and you have the complete congress experience!

On behalf of the organising committee, we invite you to join us for an educational and enjoyable four days in Belgrade.

Yours sincerely,

P. Ponikowski (Wroclaw, PL),
HFA President

P. Seferovic (Belgrade, RS),
Heart Failure 2012 Scientific Chairperson

J. Riley (London, GB),
HFA Nurse Representative

T. Eschenhagen (Hamburg, DE),
President ISHR European Section

S.D. Anker (Berlin, DE),
HFA President-Elect

Z. Papp (Debrecen, HU),
HFA Basic Sciences Representative

I. Ekman (Gothenburg, SE),
HFA Nurse Representative

D. Hilfiker-Kleiner (Hannover, DE),
Chairperson ESC WG on Myocardial Function

General information

Time Zone

Belgrade is located in the Central European time zone region - GMT+2 in May.

Electricity

As in most cities of Continental Europe, the electricity voltage in Belgrade is 220V. Electrical outlets are standard European.

Currency

The official currency in Serbia is Dinar, abbreviated RSD. Money may be exchanged in all banks and post offices, as well as in authorised bureaux de change. A bureau de change is available in the congress centre as well as two ATMs.

Climate

The climate in Belgrade is moderate continental, with four distinct seasons. Autumn lasts longer than spring, with longer sunny and warm periods. In May, the weather usually varies between 19°C and 25°C and is mainly sunny.

How to get to Belgrade

Direct flights from major European and surrounding cities:

Amsterdam	Kiev
Athens	London
Barcelona	Milan
Berlin	Moscow
Brussels	Munich
Bucharest	Oslo
Cologne	Paris
Copenhagen	Prague
Dusseldorf	Rome
Frankfurt	Sofia
Gothenburg	Stockholm
Hamburg	Vienna
Istanbul	Zurich



20 minutes by airport bus and taxi from the airport Nikola Tesla to the city centre.

(average taxi fare from the airport to the city is around €15 - Bus A1 fare is €2,50 to downtown and main Railway Station).

Official Airline



The **Star Alliance™ Members** are pleased to be appointed as the official airline network for Heart Failure 2012 and to offer pre-registered delegates special convention discounts between 10% and 20% off applicable published Business or Economy class fares, excluding website/internet fares, senior, youth and group fares, agency discount and round the world fares.

To obtain the Star Alliance™ Conventions Plus discount, please contact your local Star Alliance member, quote the following event code: **OS02A42** and submit proof of attending the event. When making your travel plans ensure that the event code is listed on your ticket.

Please visit: www.staralliance.com/conventionplus

Join us at Sava Centar

Congress Culture & Business Center
Milentija Popovica 9 St,
11070 Belgrade - SERBIA
www.savacentar.net

The Sava Centar is the largest congress and business centre in Serbia and one of the largest in Europe. It was built in 1977 as a modern building complex in one of the best areas of Belgrade, located just 10 minutes from the city centre and 20 minutes from Belgrade International Airport.



Getting to Sava Centar

Belgrade's trams, trains and buses make it easy to move around the city.

A particularly useful route for visitors is tram 2 which circles the city centre, connecting the train and bus stations with Trg Slavija and the Old Town.

Bus lines 17, 601 and 95 as well as tram lines 7, 9 and 13 connect the Sava Centar with various stops within the city.

Book your hotel online on www.escardio.org/HFA

Individual Hotel Booking

Rooms are available from 19 to 22 May 2012. All other dates are upon request and subject to hotel's availability. A limited number of rooms for individual bookings are available. For the latest list of available hotels, please visit: www.escardio.org/HFA.

	Single Room	Double Room
Balkan Hotel, 4*	€111,50	€123,00
Continental Hotel Belgrade, 4*	€165,00	€185,00
Hotel Prag, 3*	€121,50	€138,00
Hotel Excelsior, 3*	€133,00	€143,00
Belgrade City Hotel, 3*	€61,50	€90,00
Hotel Srbija, 2/3*	€51,50	€73,00

Rooms will be allocated on a first-come, first-served basis. Requests made by telephone cannot be accepted. Please note that after certain price categories have been booked out, the ESC reserves the right to confirm bookings in other categories. Upon receipt of the payment, a voucher will be issued and sent by email.

Group Hotel Booking

Group bookings (from 10 rooms) are handled separately and proposals are made on request. Hotels available for groups may not be the same as for individual bookings. Please contact us by email or fax.

Heart Failure Hotels: Tel.: +33 (0)4 92 94 76 43 - Fax: +33 (0)4 92 94 76 16

Email: HFhotels@escardio.org

Register online on www.escardio.org/HFA

- More than 10 participants, please consult the group registration pages (**special fee**)
- Less than 10 participants, please consult the third party registration pages

The standard registration fee entitles delegates to the following:

- Entry to all scientific sessions and the Exhibition
- Entry to the Opening Ceremony and Cocktail on Saturday 19 May
- The Final Programme and the Abstract CD-Rom
- Refreshment breaks (from Sunday morning to Tuesday morning)
- 1 year subscription to the European Journal of Heart Failure (valid for 2013 in paper version) included in the following fees: standard, member of the HFA of the ESC, nurse and student

	Until 19 March 2012	Until 16 April 2012	On-site
Standard	€ 600	€ 715	€ 840
Member Fee*	€ 475	€ 475	€ 840
Nurse member of the HFA of the ESC	€ 120	€ 120	€ 300
Student member of the HFA of the ESC	€ 120	€ 120	€ 300
Nurse**	€ 180	€ 240	€ 300
Student**	€ 180	€ 240	€ 300
Day Ticket	€ 330	€ 330	€ 330


* Member of the HFA of the ESC, ES-ISHR & the ESC W/G on Myocardial Function - Based on 2011 subscription

** Applications must be accompanied by a letter from the applicant's Head of Department confirming nurse or student status

If you have not registered by 16 April 2012, you will need to register on-site in Belgrade.

Heart Failure Registration: Tel.: +33 (0)4 92 94 76 12 – Fax: +33 (0)4 92 94 76 10

Email: HFRegistration@escardio.org



Congress Timetable

	BELGRADE	NIS	SOMBOR
	Saturday 19 May 2012		
14:30 16:00	Guidelines.	Heart failure with preserved ejection fraction – Update 2012	
	Satellite		
18:00 - 19:15	Opening Ceremony		
	Sunday 20 May 2012		
08:30 10:00	Atrial fibrillation and anticoagulation in heart failure.	Co-morbidities in heart failure: diabetes.	Valvular Disease. HFA Focus. Case based interactive session.
	Coffee Break - Exhibition		
11:00 12:30	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm.	Arrhythmias in heart failure - HF specialist meets the electrophysiologist. Cross talk.	Managing ischemic cardiomyopathy: new lessons from the STICH trial
	Satellite		
14:15 15:45	Valvular heart disease in heart failure	Heart failure: causes not to miss. A joint session with Latin America.	Telemonitoring - Where are we now.
	Coffee Break - Exhibition		
16:30 18:00	Late breaking trials 1.	Acute heart failure Clinical management in 2012.	Imaging heart failure - What clinicians need to know.
	Satellite		
	Monday 21 May 2012		
08:30 10:00	When drugs fail. Surgery option. A joint session with China.	The added value of biomarkers in heart failure.	Arrhythmias. HFA Focus. Case based interactive session.
	Coffee Break - Exhibition		
11:00 12:30	Controversies in cardiac resynchronisation therapy.	Emerging drug therapies for acute heart failure.	When drugs fail. Using devices in heart failure. HFA Focus. A joint session with HFSA.
	Satellite		
14:15 15:45	Late breaking trials 2.	Highlights of tomorrow.	Lifestyle: frequently asked questions.
	Coffee Break - Exhibition		
16:30 18:00	Co-morbidities in heart failure: cardiorenal syndrome.	What heart failure specialist should know about CRT.	Acute heart failure. HFA Focus. Case based interactive session.
	Tuesday 22 May 2012		
08:30 10:00	Idiopathic dilated cardiomyopathy - Diagnosis and treatment.	Optimal management of cardiogenic shock.	
	Coffee Break - Exhibition		
11:00 12:30	Highlights of the congress.	The real patient: heart failure in the elderly with co-morbidity.	

NOVI SAD	SUBOTICA	PANCEVO	PIROT
2011 & 2012 - Best of the European Journal on Heart Failure and the European Heart Journal.			
Symposia			
Welcome Cocktail			
New therapeutic devices.	Gasotransmitters and oxidative stress in the heart	Paracrine signaling: who is talking to whom and how long.	Nursing investigator award.
Posters Session - Moderated Posters			
Twenty-five years after CONSENSUS – What have we learnt about the RAAS in heart failure?	Lethal myocardial reperfusion injury: beyond mitochondrial permeability transition.	New hope for RNA-based therapies in heart failure.	Rapid fire session 1. Abstracts - Judges Choice Clinical.
Symposia			
Savremena dijagnostika i praćenje bolesnika sa srčanom insuficijencijom.	Novel aspects of Beta-Adrenergic signaling – Implications for heart failure treatment?	How to approach, treat and manage pregnancy associated heart disease.	Young investigator award for basic science.
Posters session - Moderated Posters			
Najvažnije poruke za lečenje srčane insuficijencije iz novih preporuka i konsenzus dokumenata Evropskog udruženja kardiologa.	Nuclear and sarcomeric protein alterations leading to heart failure.	Exercise training in heart failure: it's worth the effort!	Judges choice: basic science.
Symposia			
Novine u lečenju srčane insuficijencije.	Myocardial regeneration: what cell sources to use?	Integrative physiology and systems biology for clinicians.	Young investigator award for clinical research.
Posters Session - Moderated Posters			
Neurohumoralna blokada u lečenju srčane insuficijencije: sartani i blokatori beta receptora u fokusu.	Inflammation and autoimmune reactions in heart failure: biomarker, bystander or mediator.	Nuclear remodelling and Ca ²⁺ handling: key player in heart failure progression?	Rapid fire session 2. Abstracts - Judges Choice Clinical.
Symposia			
Složena klinička stanja u srčanoj insuficijenciji - prikazi bolesnika.	Cancer and the heart.	Calcium waves, leaks and dangerous currents.	HR Award session
Posters Session - Moderated Posters			
New devices for patient monitoring.	New ways in cardioprotective strategies: effects of co-morbidities and their medication.	Understanding HFpEF: lots of news!	Mitochondria in heart failure: an important target for therapy.
Listening and responding to our patients.			
Posters Session - Moderated Posters			
Lokalna sesija - sve najvažnije na kongresul	Dysfunctional ion handling in heart failure – Bystander or therapeutic target?	Why haven't we got any new therapy after 30 years of hypertrophy research?	

Attend Heart Failure 2012 to get to know what you need to know.

Our main theme this year is

“Treatment of heart failure: integrating pharmacology and technology”.

Scientific Programme

We will provide a complete programme for heart failure specialists that will enhance their knowledge, advance their skills and apprise them of the latest developments in their direct and related fields of activity. The added value of this year's programme is the collaboration with the European Section of ISHR, through a track dedicated to research for both clinicians and researchers. A further collaboration with the ESC WG on Myocardial function is an opportunity to explore specific topics with dedicated experts.

Main themes and objectives

▪ Treatment of heart failure: integrating pharmacology and technology

Review treatment of congestion, a major unmet need in heart failure, as a main objective. Revisit biomarkers and guidelines oriented individual strategies for the most vulnerable patients. Compare your experience with the leading experts in the field of acute heart failure and optimisation of care for the most complex patients. Explore the recent advances in management of heart failure patients with diabetes, obesity, atrial fibrillation, and ventricular arrhythmias. Translate the results of the latest randomised trials into clinically detectable improved outcomes.

▪ Co-morbidities and heart failure

Explore in-depth the topics of co-morbidities and heart failure - Chronic Obstructive Pulmonary Disease (COPD), diabetes, hypertension and include new areas such as cancer, cardio-renal syndrome through main sessions led by experts but also with the more practical angle of interactive educational sessions based on actual clinical cases.

▪ Devices and Technology for heart failure in 2012

Discuss critical decision making in the role of ICDs and CRT implantations and therapies. Review patient selection criteria for the use of implantable LVADs for heart failure treatment. Explore the developments of telemonitoring and other monitoring management.

▪ Education and Guidelines

Understand the clinical implications of the latest guidelines for the complex clinical scenarios. Learn how to improve outcomes in the heart failure population with a practical application of the HFA guidelines to assist all heart failure professionals in the frequent controversies of their daily practice.

NEW **A first presentation of the ESC Guidelines on the diagnosis & treatment of heart failure - by the HFA Task force involved in the redaction - Guidelines aim to present all the relevant evidence on a particular clinical issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical medical decision-making.**

▪ Latest Updates

On devices and therapies, ongoing trials and research to understand the upcoming technologies, drugs and development in heart failure. Hear about the latest clinical trial data and patient registries.

▪ Basic Science and Basic Science translated for the clinician

When researchers meet and interact with clinicians to discuss the science that will lead tomorrow's translational initiatives. Sessions aimed at researchers, PhD students and early career scientists as well as clinicians and all health care providers.

Continued Medical Education



The Heart Failure Congress 2012 is currently under review for accreditation by the European Board for Accreditation in Cardiology (EBAC) for external credits. The accreditation results will be announced online. EBAC credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). Detailed instructions for converting these credits to AMA PRA Category 1 Credits are available on the AMA website.

The information published in this programme is accurate at the time it goes to press. The Scientific Committee reserves the right to amend it at any time. To view all modifications after the publication date, please visit the Scientific programme online on www.escardio.org/HFA.

Special sessions - not to be missed!

SATURDAY, 19 MAY 2012 - 14:30 - 16:00

Best 2011 & 2012

Best of the European Journal on Heart Failure and the European Heart Journal

Room: Novi Sad

Chairpersons: M. Komajda (Paris, FR) - P. Ponikowski (Wroclaw, PL)

- Biomarkers - A. Maisel (San Diego, US)
- Patient care - T. Jaarsma (Norrköping, SE)
- Imaging - F.J. Pinto (Lisbon, PT)
- Devices - D.J. van Veldhuisen (Groningen, NL)
- Drugs - H. Krum (Melbourne, AU)

MONDAY, 21 MAY 2012 - 14:15 - 15:45

Highlights of tomorrow.

Room: Nis

Chairpersons: S.D. Anker (Berlin, DE) - F. Ruschitzka (Zurich, CH)

Industry representatives will present highlights of their current programme of research in heart failure and their views about the field more generally. They will inform the audience about projects in the pipeline and phase II/III trials. Each presentation will be concluded by panel discussion. Questions from the audience are encouraged.

TUESDAY, 22 MAY 2012 - 08:30 - 10:00

Highlights of the congress - Basic science.

Room: Subotica

Basic Science Scientific Programme 2012 in a nutshell!

Experts will present highlights on the scientific content presented in Belgrade.

TUESDAY, 22 MAY 2012 - 11:00 - 12:30

Highlights of the congress.

Room: Belgrade

Chairpersons: P. Seferovic (Belgrade, RS) - S.D. Anker (Berlin, DE) - P. Ponikowski (Wroclaw, PL)

- Basic science - T. Thum (Hannover, DE)
- Patient care - J. Riley (London, GB)
- Diagnosis / Imaging / Pathophysiology - F. Braunschweig (Stockholm, SE)
- HFpEF: heart failure with preserved ejection fraction - C. Tschoepe (Berlin, DE)
- Drug treatment - A.P. Maggioni (Florence, IT)
- Devices - F. Ruschitzka (Zurich, CH)

Case based interactive sessions - HFA Focus

These sessions are based on clinical cases which will be presented and discussed with experts sitting on the panel and audience in the room. Practical step by step management of the case, do and don't, what would you do?

Concluded by recommendations based on the new ESC Guidelines on the diagnosis and treatment of heart failure.

SUNDAY, 20 MAY 2012 - 08:30 - 10:00

Valvular disease.

Room: Sombor

HFA Focus. Case based interactive session

MONDAY, 21 MAY 2012 - 08:30 - 10:00

Arrhythmias.

Room: Sombor

HFA Focus. Case based interactive session

Chairpersons: K. Dickstein (Stavanger, NO) - F. Ruschitzka (Zurich, CH)

MONDAY, 21 MAY 2012 - 11:00 - 12:30

When drugs fail - Using devices in heart failure.

Room: Sombor

HFA Focus. A joint session with the Heart Failure Society of America (HFA)

Chairpersons: S.D. Anker (Berlin, DE) - B.M. Massie (San Francisco, US)

MONDAY, 21 MAY 2012 - 16:30 - 18:00

Acute heart failure.

Room: Sombor

HFA Focus. Case based interactive session.

Chairpersons: G.S. Filippatos (Athens, GR) - P. Ponikowski (Wroclaw, PL)

Treatment of heart failure: Integrating Pharmacology and Technology

SATURDAY, 19 MAY 2012 - 14:30 - 16:00

Coronary heart disease in heart failure: what the clinician should know.

Room: Pancero

- Chairpersons:** D. Mann (St.Louis [US]) - D. Tousoulis (Athens, GR)
- Imaging and myocardial ischemia testing. - G.M.C. Rosano (Roma, IT)
 - Viability testing - Is it necessary? - M. Petrie (Glasgow, GB)
 - New drug treatment - J.T. Parissis (Athens, GR)
 - Revascularisation - V. Falk (Zurich, CH)
 - Panel discussions

SUNDAY, 20 MAY 2012 - 08:30 - 10:00

Atrial fibrillation and anticoagulation in heart failure.

Room: Belgrade

- Chairpersons:** J. Cleland (Kingston Upon Hull, UK) - O. Chioncel (Bucarest, RO)
- AF: how big is the problem? - A.P. Maggioni (Florence, IT)
 - AF therapy: rate or rhythm control? - G.M.C. Rosano (Roma, IT)
 - AF therapy: when to consider ablation? - A. Goette (Paderborn, DE)
 - Anticoagulation in patients with SR vs AF? - S. Homma (New York, US)
 - Novel anticoagulants and their potential for heart failure patients - G.Y.H. Lip (Birmingham, GB)

SUNDAY, 20 MAY 2012 - 11:00 - 12:30

Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm.

Room: Belgrade

- Chairpersons:** G.Y.H. Lip (Birmingham, GB) - P. Ponikowski (Wroclaw, PL)
- Epidemiology, pathophysiology and clinical assessment. - F. Marin (Murcia, ES)
 - Observational studies and older trials - G. Filippatos (Athens, GR)
 - What do the randomized trials tell us - S. Anker (Berlin, DE)
 - Consensus statements - P. Ponikowski (Wroclaw, PL), G.Y.H. Lip (Birmingham, GB)

SUNDAY, 20 MAY 2012 - 11:00 - 12:30

Twenty-five years after CONSENSUS.

Room: Novi Sad

What have we learnt about the RAAS in heart failure?

- Chairpersons:** A.J.S. Coats (Norwich, GB) - B.M. Massie (San Francisco, US)
- ACE inhibitors: still the gold standard? - L. Kober (Gentofte, DK)
 - ARBs - What can we conclude? - K. Swedberg (Gothenburg, SE)
 - Aldosterone/MRA - The complete picture? - F. Zannad (Nancy, FR)
 - Renin inhibitors: still on trial - H. Krum (Melbourne, AU)
 - ARNis - More than blocking the RAAS? - J.J.V. McMurray (Glasgow, GB)

MONDAY, 21 MAY 2012 - 08:30 - 10:00

When drugs fail - Surgery option

Room: Belgrade

A joint session under construction with ESC China affiliates.

Details available soon on www.escardio.org/HFA

MONDAY, 21 MAY 2012 - 08:30 - 10:00

The added value of biomarkers in heart failure.

Room: Nis

- Chairpersons:** W.F. Peacock (Cleveland, US) - S. Von Haehling (Berlin, DE)
- Application of new biomarkers in daily practice: what evidence is needed? - A.W. Hoes (Utrecht, NL)
 - Pitfalls in use of biomarkers in heart failure - A.A. Voors (Groningen, NL)
 - Natriuretic peptides: how to use them? - A. Maisel (San Diego, US)
 - Biomarkers guided therapy: targeting iron - W. Doehner (Berlin, DE)
 - Recent additions to the biomarker portfolio - G.S. Filippatos (Athens, GR)

MONDAY, 21 MAY 2012 - 11:00 - 12:30

Emerging drug therapies for acute heart failure.

Room: Nis

- Chairpersons:** V. Mitrovic (Bad Nauheim, DE) - J. Stepinska (Warsaw, PL)
- Natriuretic peptide - G.S. Filippatos (Athens, GR)
 - Relaxin - M. Metra (Brescia, IT)
 - Guanylate cyclase modulators - M. Gheorghide (Chicago, US)
 - RAAS inhibitors - A.P. Maggioni (Florence, IT)
 - Cardiac myosin activators - J.R. Teerlink (San Francisco, US)

MONDAY, 21 MAY 2012 - 16:30 - 18:00

What heart failure specialist should know about CRT.

Room: Nis

- Chairpersons:** F. Ruschitzka (Zurich, CH) - C. Tschoepe (Berlin, DE)
- How to choose the right patient - K. Dickstein (Stavanger, NO)
 - How to: implantation procedures - M. Gasparini (Rozzano, IT)
 - How to optimise follow up - Z. Kalarus (Zabrze, PL)
 - How to handle non-responders - C. Stellbrink (Bielefeld, DE)
 - Panel discussions

TUESDAY, 22 MAY 2012 - 08:30 - 10:00

Idiopathic dilated cardiomyopathy - Diagnosis and treatment.

Room: Belgrade

Chairpersons: M. Petrie (Glasgow, GB) - A. Keren (Jerusalem, IL)

- What is DCM? - A. Keren (Jerusalem, IL)
- How should we investigate it? - M. Volterrani (Rome, IT)
- How should we treat it? - M. Petrie (Glasgow, GB)
- Panel discussions

TUESDAY, 22 MAY 2012 - 08:30 - 10:00

Optimal management of cardiogenic shock.

Room: Nis

Chairpersons: A. Mebazaa (Paris, FR) - A.D. Ristic (Belgrade, RS)

- Benefits of mechanical ventilation - J. Masip (Barcelona, ES)
- Impact of medical management on outcome - M. Metra (Brescia, IT)
- Indications of mechanical support - M.R. Costanzo (Naperville, US)
- Organ dysfunction - J.P.E. Lassus (Espoo, FI)
- Panel discussions

Co-morbidities and heart failure

SUNDAY, 20 MAY 2012 - 08:30 - 10:00

Co-morbidities in heart failure: diabetes.

Room: Nis

Chairpersons: V. Mareev (Moscow, RU) - To be announced

- Diabetic cardiomyopathy: does it exist? - W.J. Paulus (Amsterdam, NL)
- Consequences of diabetes and insulin resistance in heart failure - W. Doehner (Berlin, DE)
- How to treat diabetes now - P. Seferovic (Belgrade, RS)
- New treatments and trials - J.J.V. McMurray (Glasgow, GB)
- Panel discussions

MONDAY, 21 MAY 2012 - 16:30 - 18:00

Co-morbidities in heart failure: cardiorenal syndrome.

Room: Belgrade

Chairpersons: A.P. Maggioni (Florence, IT) - E.A. Jankowska (Wroclaw, PL)

- Definition and epidemiology - A.A. Voors (Groningen, NL)
- Pathophysiology - C. Ronco (Vicenza, IT)
- Management - J.T. Parissis (Athens, GR)
- Anemia and iron deficiency - S.D. Anker (Berlin, DE)
- Panel discussions

TUESDAY, 22 MAY 2012 - 11:00 - 12:30

The real patient: heart failure in the elderly with co-morbidity.

Room: Nis

Chairpersons: J. Nanas (Athens, GR) - F.H. Rutten (Utrecht, NL)

- Recognising slow onset heart failure in the elderly: time for diagnostic algorithms? - A.W. Hoes (Utrecht, NL)
- How to adjust drug therapy in elderly heart failure patients - C. O'Connor (Durham, US)
- Anti-coagulation in elderly heart failure patients - S. Homma (New York, US)
- How do we use biomarkers (incl. kidney function) tests in the elderly - C. Ronco (Vicenza, IT)
- Palliative care in the elderly patient with HFpEF and multi-morbidity - To be announced

Devices and Technology for heart failure in 2012

SUNDAY, 20 MAY 2012 - 08:30 - 10:00

New therapeutic devices.

Room: Novi Sad

Chairpersons: S.D. Anker (Berlin, DE) - To be announced

- Baroreceptor stimulation - G. Hasenfuss (Goettingen, DE)
- Vagal nerve stimulation - F. Zannad (Nancy, FR)
- Phrenic nerve stimulation - P. Ponikowski (Wroclaw, PL)
- Renal sympathetic denervation - D. Francis (London, GB)
- Mitral clip - O.W. Franzen (Copenhagen, DK)
- Other devices
- Panel discussions

SUNDAY, 20 MAY 2012 - 14:15 - 15:45

Telemonitoring - Where are we now.

Room: Sombor

Chairpersons: J. Riley (London, GB) - A. Kavoliuniene (Kaunas, LT)

- Insights from clinical trials: telephone monitoring and nurses - J. Riley (London, GB)
- Insights from clinical trials: remote patient management - F. Koehler (Berlin, DE)
- Active role for patients? - I. Ekman (Gothenburg, SE)
- Different models for different patients - S. Von Haehling (Berlin, DE)
- Why do we need telemonitoring solutions? - J.G.F. Cleland (Kingston Upon Hull, GB)

SUNDAY, 20 MAY 2012 - 16:30 - 18:00

Imaging heart failure - What clinicians need to know.

Room: Sombor

Chairpersons: F.J. Pinto (Lisbon, PT) - To be announced

- Echocardiography - Do we need more than ejection fraction? - B.A. Popescu (Bucharest, RO)
- CMR: ever necessary? - P. A. Kaufmann (Zurich, CH)
- Nuclear: still relevant? - A.N. Kitsiou (Athens, GR)
- PET/CT - P.G. Camici (Milan, IT)
- Panel discussions

MONDAY, 21 MAY 2012 - 11:00 - 12:30

Controversies in cardiac resynchronisation therapy.

Room: Belgrade

Chairpersons: K. Dickstein (Stavanger, NO) - To be announced

- Atrial fibrillation - A. Auricchio (Lugano, CH)
- Non left bundle branch block - C. Stellbrink (Bielefeld, DE)
- When to upgrade a conventional pacemaker - C. Linde (Stockholm, SE)
- Narrow QRS - F. Ruschitzka (Zurich, CH)
- Left ventricular ejection fraction >35 - D.A. Kass (Baltimore, US)

MONDAY, 21 MAY 2012 - 16:30 - 18:00

New devices for patient monitoring.

Room: Novi Sad

Chairpersons: F. Koehler (Berlin, DE) - P. Seferovic (Belgrade, RS)

- Fluid balance / Impedance - D.J. van Veldhuisen (Groningen, NL)
- Haemodynamics sensing - To be announced
- Rhythm assessments - F. Braunschweig (Stockholm, SE)
- Home biomarkers - A. Maisel (San Diego, US)
- How to integrate new device and manage information - J.G.F. Cleland (Kingston Upon Hull, GB)

Education and Guidelines

SATURDAY, 19 MAY 2012 - 14:30 - 16:00

Guidelines.

Room: Nis

Chairpersons: F. Zannad (Nancy, France) - J.J.V. McMurray (Glasgow, GB)

- Overview of the 2012 heart failure guidelines - J.J.V. McMurray (Glasgow, GB)
- Update on diagnosis of heart failure - F.H. Rutten (Utrecht, NL)
- Update on pharmacological treatment of heart failure - L. Kober (Copenhagen, DE)
- Update on implanted devices - K. Dickstein (Stavanger, NO)
- Update on surgery, mechanical circulatory support and transplantation. - S. Adamopoulos (Athens, GR)

SUNDAY, 20 MAY 2012 - 11:00 - 12:30

Valvular heart disease in heart failure.

Room: Belgrade

Chairpersons: A. Vahanian (Paris, FR), P.M. Gatzov (Sofia, BG)

- How to assess valvular heart disease? - A. Vahanian (Paris, FR)
- Management of mitral regurgitation - O. Alfieri (Brescia, IT)
- Management of aortic stenosis - R. Lange (Munich, DE)
- Management of tricuspid regurgitation - A. Pitsis (Thessaloniki, GR)
- Panel discussions

SUNDAY, 20 MAY 2012 - 11:00 - 12:30

Arrhythmias in heart failure - HF specialist meets the electrophysiologist. Cross talk

Room: Nis

Chairpersons: J. Brugada Terradellas (Barcelona, ES) - A. Cohen-Solal (Paris, FR)

Atrial fibrillation

- Heart failure specialists' view point - R. Dabrowski (Warsaw, PL)
- Electrophysiologists' view point - A. Goette (Paderborn, DE)

Ventricular tachycardia

- Heart failure specialists' view point - To be announced
- Electrophysiologists' view point - To be announced

SUNDAY, 20 MAY 2012 - 14:15 - 15:45

Heart failure: causes not to miss.

Room: Nis

A joint session currently under construction with ESC Latin America affiliates.

Details available soon on www.escardio.org/HFA

Latest Updates

SATURDAY, 19 MAY 2012 - 14:30 - 16:00

Heart failure with preserved ejection fraction - Update 2012 - State of the art.

Room: Nis

Chairpersons: W.J. Paulus (Amsterdam, NL) - D.L. Brutsaert (Antwerp, BE)

- Pathophysiology of HFpEF - What is new and clinically relevant? - D.A. Kass (Baltimore, US)
- Diagnosis - Is it really heart failure? - B.M. Pieske (Graz, AT)
- Biomarkers and imaging - Can they assure the diagnosis? - S. Solomon (Boston, US)
- Current and future management of HFpEF - To be announced
- Panel discussions

SUNDAY, 20 MAY 2012 - 16:30 - 18:00

Late breaking trials 1.

Room: Belgrade

Chairpersons: S.D. Anker (Berlin, DE) - K. Swedberg (Gothenburg, SE)

Latest trials: presentation by investigators followed by a discussant review and questions from audience and chairpersons.

SUNDAY, 20 MAY 2012 - 11:00 - 12:30

Managing ischemic cardiomyopathy: new lessons from the STICH trial

Room: Sombor

Chairpersons: S. Gradinac (Belgrade, RS) - J. Cleland (Kingston Upon Hull, GB)

- Selecting the optimal patient for surgical revascularization: towards a STICH score - E. Velazquez (Durham, US)
- Prevalence and prognostic role of right ventricular dysfunction in ischemic heart failure: results from STICH
T. Kukulski (Zabrze, PL)
- Influence of failure to implement assigned treatment (Crossover) on survival in STICH - T. Doenst (Jena, DE)
- Left ventricular size before and after CABG with and without SVR: Ventricular remodeling surgery post-STICH
J.L. Rouleau (Montreal, CA)

SUNDAY, 20 MAY 2012 - 16:30 - 18:00

Acute heart failure - Clinical management in 2012.

Room: Nis

Chairpersons: M. Gheorghiu (Chicago, US) - A. Mebazaa (Paris, FR)

- Pre-hospital treatment - F.H. Rutten (Utrecht, NL)
- Emergency department management - W.F. Peacock (Cleveland, US)
- ICU management: special cases of cardiogenic shock - M.R. Costanzo (Naperville, US)
- In hospital management - P. Ponikowski (Wroclaw, PL)
- Post discharge management - G.S. Filippatos (Athens, GR)

MONDAY, 21 MAY 2012 - 14:15 - 15:45

Late breaking trials 2.

Room: Belgrade

Chairpersons: P. Ponikowski (Wroclaw, PL) - P. Seferovic (Belgrade, RS)

Latest trials: presentation by investigators followed by a discussant review and questions from audience and chairpersons.

Patient care

MONDAY, 21 MAY 2012 - 14:15 - 15:45

Lifestyle: frequently asked questions.

Room: Sombor

Chairpersons: J. Riley (London, GB) - A.W. Hoes (Utrecht, NL) - I. Ekman (Gothenburg, SE)

- Sex - T. Jaarsma (Norrköping, SE)
- Diet - M. Lainscak (Golnik, SI)
- Driving and travel - T.A. McDonagh (London, GB)
- Exercise - V. Conraads (Edegem, BE)

TUESDAY, 22 MAY 2012 - 08:30 - 10:00

Listening and responding to our patients.

Room: Novi Sad

Chairpersons: T.A. McDonagh (London, GB) - A. Wolf (Gothenburg, SE)

- Delivering person-centered care: a new way of organising care? - I. Ekman (Gothenburg, SE)
- Caring for relatives - A. Stromberg (Linköping, SE)
- Providing emotional support - N. Damen (Tilburg, NL)
- Supporting the expert patient: a new role for technology? - J. Riley (London, GB)
- Panel discussions

Basic Science Translated for the Clinician

SUNDAY, 20 MAY 2012 - 14:15 - 15:45

How to approach, treat and manage pregnancy associated heart disease.

Room: Pancevo

Chairpersons: A.M. Shah (London, GB) - S. Janssens (Leuven, BE)

- Definition and epidemiology of pregnancy-associated heart disease - M. Schaufelberger (Gothenburg, SE)
- Update on the European peri-paertum cardiomyopathy registry - To be announced
- Impaired endothelial to cardiomyocyte cross-talk responsible for slow recovery from PPCM
D. Hilfiker-Kleiner (Hannover, DE)
- New biomarkers for diagnosis and risk stratification of women with heart disease in pregnancy
V. Regitz-Zagrosek (Berlin, DE)
- Multi-media approach implementing cutting-edge technology into educational and preventative health programme in women - K. Sliwa-Hahnle (Cape Town, ZA)

SUNDAY, 20 MAY 2012 - 16:30 - 18:00

Exercise training in heart failure: it's worth the effort!

Room: Pancevo

Chairpersons: M.F. Piepoli (Piacenza, IT) - D. Gaita (Timisoara, RO)

- Physical activity and risk of heart failure - A.J.S. Coats (Norwich, GB)
- Exercise training and cardiac remodelling - D.J.G.M. Duncker (Rotterdam, NL)
- Exercise training and vascular remodelling - S. Adamopoulos (Athens, GR)
- Clinical trial evidence for exercise training in heart failure - C. O'Connor (Durham, US)
- How to implement exercise training in clinical practice - V. Conraads (Edegem, BE)

MONDAY, 21 MAY 2012 - 14:15 - 15:45

Calcium waves, leaks and dangerous currents.

Room: Pancevo

Chairpersons: F.R. Heinzel (Graz, AT) - L. Neyses (Manchester, GB)

- Roles of RyR2 and SERCA2 in arrhythmogenesis - D.A. Eisner (Manchester, GB)
- CaMKII as a critical modulator of SR function - To be announced
- Inherited SR-linked arrhythmias - S.G. Priori (Pavia, IT)
- Translation into clinical arena - G. Hasenfuss (Gottingen, DE)

MONDAY, 21 MAY 2012 - 16:30 - 18:00

Understanding HFpEF: lots of news!

Room: Pancevo

Chairpersons: To be announced - B.M. Pieske (Graz, AT)

- Atrial function - V. Melenovsky (Prague, CZ)
- New imaging modalities in HFpEF - E. Kraigher-Krainer (Graz, AT)
- Exercise testing - M.P. Frenneaux (Aberdeen, GB)
- Invasive haemodynamics - D.A. Kass (Baltimore, US)
- New drugs in the pipeline for HFpEF - M. Pfeffer (Boston, US)

TUESDAY, 22 MAY 2012 - 11:00 - 12:30

Why haven't we got any new therapy after 30 years of hypertrophy research?

Room: Pancevo

Chairpersons: T. Eschenhagen (Hamburg, DE) - S.E. Harding (London, GB)

- Insights into hypertrophic remodelling - State of the art - L. Neyses (Manchester, GB)
- We are on the right track - Therapeutic success will come - To be announced
- The concept is wrong - No way into new therapies - To be announced
- Integration from a clinical perspective - M. Pfeffer (Boston, US)

Basic Science

SUNDAY, 20 MAY 2012 - 08:30 - 10:00

Paracrine signaling: who is talking to whom and how long.

Room: Pancevo

Chairpersons: T. Thum (Hannover, DE) - D.L. Brutsaert (Antwerp, BE)

- Neuregulin-1 and its potential role in the control of cardiac function - G.W.A. De Keulenaer (Wilrijk, BE)
- The importance of the cardiac microenvironment - D. Hilfiker-Kleiner (Hannover, DE)
- Cardiac metabolism and VEGF regulation - To be announced
- Myofibroblasts in heart failure - mediators of remodelling and arrhythmogenicity? - To be announced
- Fibroblast myocyte interactions - S. Engelhardt (Munich, DE)

SUNDAY, 20 MAY 2012 - 08:30 - 10:00

Gasotransmitters and oxidative stress in the heart.

Room: Subotica

Chairpersons: P. Ferdinandy (Szeged, HU) - G. Valen (Oslo, NO)

- Neuronal NO Synthase-Derived NO - To be announced
- Novel pharmacological approaches targeting NO - D. Tousoulis (Athens, GR)
- Hydrogen sulfide signaling in the heart - G.F. Baxter (Cardiff, GB)
- Carbon monoxide signaling in the heart - C. Peers (Leeds, GB)
- Modulating NOS uncoupling: a new therapeutic avenue? - A. Moens (Hoesbroek, NL)

SUNDAY, 20 MAY 2012 - 11:00 - 12:30

New hope for RNA-based therapies in heart failure.

Room: Pancevo

Chairpersons: S. Engelhardt (Munich, DE) - M. Mayr (London, GB)

- Targeting non-coding RNAs implicated in cardiomyocyte regeneration - M. Giacca (Trieste, IT)
- Targeting microRNA implicated in cardiomyocyte function - L.J. De Windt (Maastricht, NL)
- Targeting fibrosis microRNAs to treat heart failure - T. Thum (Hannover, DE)
- Correcting gene defects in muscular dystrophy - T. Voit (Paris, FR)
- Alternative approaches: AAV-mediated gene transfer to treat heart failure - R.J. Hajjar (New York, US)

SUNDAY, 20 MAY 2012 - 11:00 - 12:30

Lethal myocardial reperfusion injury: beyond mitochondrial permeability transition.

Room: Subotica

Chairpersons: F. Di Lisa (Padua, IT) - R. Schulz (Giessen, DE)

- Cardiomyocyte cell death: apoptosis, necrosis, autophagy - D.J. Hausenloy (London, GB)
- Factors determining the type of cell death during ischemia/reperfusion - D. Garcia-Dorado (Barcelona, ES)
- Microvascular factors in myocardial reperfusion injury - G. Heusch (Essen, DE)
- Mitochondrial permeability transition: not only a cell death determinant - J. Molkenin (Cincinnati, US)
- Ischemia-reperfusion injury: which therapies after 20 years of research? - H.N. Sabbah (Detroit, US)

SUNDAY, 20 MAY 2012 - 14:15 - 15:45

Novel aspects of Beta-Adrenergic signaling - Implications for heart failure treatment?

Room: Subotica

Chairpersons: S.E. Harding (London, GB) - To be announced

- Redistribution of beta-adrenergic receptors in heart failure - V.O. Nikolaev (Wurzburg, DE)
- PI3 kinase and cAMP signaling microdomains - E. Hirsch (Turin, IT)
- Role of phosphodiesterase 4 for cardiac arrhythmias - G. Vandecasteele (Chatenay-Malabry, FR)
- Beta-blockers - old dogs, new tricks? - C. Maack (Hamburg, DE)
- Heart rate and heart rate modulation in HfpEF - M. Boehm (Hamburg, DE)

SUNDAY, 20 MAY 2012 - 16:30 - 18:00

Nuclear and sarcomeric protein alterations leading to heart failure.

Room: Subotica

Chairpersons: T. Eschenhagen (Hamburg, DE) - W.J. Paulus (Amsterdam, NL)

- ISHR Keith Reiner lecture - M. Avkiran (London, GB)
- Regional heterogeneity in sarcomere function and cardiac disease - Z. Papp (Debrecen, HU)
- Impaired Frank-Starling mechanism in hypertrophy and failure? - J. van der Velden (Amsterdam, NL)
- Increased energy usage of the sarcomeres as cause of cardiac hypertrophy - C. Poggesi (Florence, IT)

MONDAY, 21 MAY 2012 - 08:30 - 10:00

Integrative physiology and systems biology for clinicians.

Room: Pancevo

Chairpersons: B.K. Pedersen (Copenhagen, DK) - A.R. Pries (Berlin, DE)

- Introduction for clinicians - L. Neyses (Manchester, GB)
- Systems biological strategies in cardiovascular disease - M. Oresic (Espoo, FI)
- Clinical proteomics in cardiovascular disease - F. Pinet (Lille, FR)
- Clinical metabolomics of LV remodelling - M. Mamas (Manchester, GB)
- Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures - To be announced

MONDAY, 21 MAY 2012 - 08:30 - 10:00

Myocardial regeneration: what cell sources to use?

Room: Subotica

Chairpersons: T. Eschenhagen (Hamburg, DE) - To be announced

- Embryonic and gonadal stem cells: where are we in 2012? - W.-H. Zimmermann (Gottingen, DE)
- IPS cells: potential and pitfalls - K.-L. Laugwitz (Munich, DE)
- Myocardial regeneration: do we need cells or the factors that they produce? - K.C. Wollert (Hannover, DE)
- Clinical perspective of adult bone marrow cell therapy - S. Janssens (Leuven, BE)

MONDAY, 21 MAY 2012 - 11:00 - 12:30

Nuclear remodelling and Ca²⁺ handling: key player in heart failure progression?

Room: Pancevo

Chairpersons: B.M. Pieske (Graz, AT) - R. Fischmeister (Chatenay-Malabry, FR)

- The concept of excitation-transcription coupling - D.M. Bers (Davis, US)
- Structural remodelling of the nucleus in hypertrophy and heart failure - J. Kockskaemper (Marburg, DE)
- Altered ion handling of the nucleus in hypertrophy and failure - S. Ljubojevic (Graz, AT)
- Surface-to nucleus communication: new insights into IP3-dependent regulation of cardiac remodelling - M. Bootman (GB)
- Biology and therapeutic implications of HDACs in the heart. - T.A. McKinsey (Denver, US)

MONDAY, 21 MAY 2012 - 11:00 - 12:30

Inflammation and autoimmune reactions in heart failure: biomarker, bystander or mediator.

Room: Subotica

Chairpersons: M. Fu (Gothenburg, SE) - R. Jahns (Wurzburg, DE)

- Inflammation and immunity: how it occurs and how to measure it? - B. Maisch (Marburg, DE)
- Metabolic consequences of inflammation in heart failure? - E.A. Jankowska (Wroclaw, PL)
- Autoantibodies - Immunoabsorption and epitope-mimicking cyclic peptides - R. Jahns (Wurzburg, DE)
- Toll-like receptors as potential therapeutic targets in cardiac dysfunction - D. Mann (St. Louis, US)
- Insight from anti-inflammatory and immunoregulatory trials in chronic heart failure - L. Gullestad (Oslo, NO)

MONDAY, 21 MAY 2012 - 14:15 - 15:45

Cancer and the heart.

Room: Subotica

Chairpersons: D. Hilfiker-Kleiner (Hannover, DE) - E. Hirsch (Turin, IT)

- Cardiac function in cancer patients - What do we know? - S. Von Haehling (Berlin, DE)
- Mechanisms of chemotherapy induced cardiotoxicity - T.L. Force (Philadelphia, US)
- Using cardiac biomarkers & treating cardiotoxicity in cancer - D. Cardinale (Milan, IT)
- Progressive loss of cardiac function and muscle in cancer cachexia: time to treat the heart! - J. Springer (Berlin, DE)
- Treating cancer patients with heart failure drugs: clinical data - A.J.S. Coats (Norwich, GB)

MONDAY, 21 MAY 2012 - 16:30 - 18:00

New ways in cardioprotective strategies: effects of co-morbidities and their medication.

Room: Subotica

Chairpersons: B.J. Mcdermott (Belfast, GB) - G. Heusch (Essen, DE)

- Cardioprotective signaling in aging - R. Schulz (Giessen, DE)
- Drug-induced inhibition of endogenous cardioprotection: new safety considerations - E. Golomb (IL)
- Cardioprotective signaling in diabetes - D.J. Hausenloy (London, GB)
- Effects of hyperlipidemia and statins on cardioprotective signaling - P. Ferdinandy (Szeged, HU)
- The role of mitochondrial MAO in cardioprotection - F. Di Lisa (Padua, IT)

MONDAY, 21 MAY 2012 - 16:30 - 18:00

Mitochondria in heart failure: an important target for therapy.

Room: Piroc

Chairpersons: D.M. Bers (Davis, US) - C. Maack (Hamburg, DE)

- Energy metabolism in heart failure - R.F. Ventura-Clapier (Chatenay-Malabry, FR)
- Abnormalities of structure and function of mitochondria in heart failure - H.N. Sabbah (Detroit, US)
- Mitochondria & tissue iron - S. Von Haehling (Berlin, DE)
- Mitochondria DNA mutations and heart failure - L. Bindoff (Bergen, NO)
- Oxidative stress and mitochondrial DNA damage in heart failure - A.J. Murray (Oxford, GB)

TUESDAY, 22 MAY 2012 - 08:30 - 10:00

Novel mechanisms of cell death or survival in heart failure.

Room: Pancevo

Chairpersons: F. Di Lisa (Padua, IT) - A.M. Shah (London, GB)

- Mitophagy and sterile inflammation - K. Otsu (Osaka, JP)
- The mitochondrial PTP and cell necrosis - J. Molkenin (Cincinnati, US)
- Fatty acids trigger mitochondrion-dependent necrosis - F. Madeo (Graz, AT)
- Beta3-receptor signaling and myocyte survival - J.-L. Balligand (Brussels, BE)
- The protective neuregulin-1 / Erb axis - G.W.A. De Keulenaer (Wilrijk, BE)

TUESDAY, 22 MAY 2012 - 11:00 - 12:30

Dysfunctional ion handling in heart failure - Bystander or therapeutic target?

Room: Subotica

Chairpersons: D.A. Eisner (Manchester, GB) - G. Hasenfuss (Göttingen, DE)

- Dysfunctional ion handling in heart failure - State of the art - D.M. Bers (Davis, US)
- Pharmacological modulation of the NCX - What is the evidence? - G. Antoons (Leuven, BE)
- Mechanosensitive ion channels in the failing heart - Focus on TRP channels - T. Gudermann (Munich, DE)
- Alterations of atrial Ca²⁺ handling in heart failure - Cause or consequence for atrial fibrillation? U. Schotten (Maastricht, NL)

Local Language Sessions

Sessions held in Serbo-Croatian only, no translation available.

SUNDAY, 20 MAY 2012 - 14:15 - 15:45

Savremena dijagnostika i praćenje bolesnika sa srčanom insuficijencijom.

Room: Novi Sad

Chairpersons: N. Cemerlic Adic (Šremska Kamenica, RS), D. Vulić (Banja Luka, BA)

- Kako primeniti biomarkere u dijagnostici i lečenju srčane insuficijencije? - S. Dodic (Šremska Kamenica, RS)
- Značaj ehokardiografije u proceni bolesnika sa srčanom insuficijencijom - A.N. Neskovic (Belgrade, RS)
- Magnetna rezonanca i multi-slajsna kompjuterizovana tomografija u srčanoj insuficijenciji R. Maksimovic (Belgrade, RS)
- Od elektrokardiografije do invazivne dijagnostike u proceni srčane insuficijencije - V. Vukcevic (Belgrade, RS)

SUNDAY, 20 MAY 2012 - 16:30 - 18:00

Najvažnije poruke za lečenje srčane insuficijencije iz novih preporuka i konsenzus dokumenata Evropskog udruženja kardiologa

Room: Novi Sad

Chairpersons: Z. Vasiljević (Belgrade, RS), V. Mitrović (Bad Nauheim, DE)

- Šta je novo u preporukama za srčanu insuficijenciju Evropskog udruženja kardiologa 2012? P.M. Seferovic (Belgrade, RS)
- Peripartalna kardiomiopatija - M. Deljanin-Ilic (Nis, RS)
- Lečenje dislipidemija i dijabetesa kod bolesnika sa srčanom insuficijencijom - N.M. Lalic (Belgrade, RS)
- Pejsmejkleri, kardioverter defibrilatori i drugi implantabilni uređaji u lečenju srčane insuficijencij G. Milasinovic (Belgrade, RS)

MONDAY, 21 MAY 2012 - 08:30 - 10:00

Novine u lečenju srčane insuficijencije.

Room: Novi Sad

Chairpersons: E. Rajčević (Sarajevo, BA), M. Pavlović (Nis, RS)

- Akutna srčana insuficijencija: savremeni terapijski pristup - V. Mitrovic (Bad Nauheim, DE)
- Savremena medikamentozna terapija hronične srčane insuficijencije - D. Milicic (Zagreb, HR)
- Nekoronarne perkutane intervencije u lečenju srčane insuficijencije - S. Kedev (Skoplje, MK)
- Značaj kardiohirurgije u lečenju srčane insuficijencije kada nije dostupna transplantacija srca: indikacije, tehnike, dugoročni rezultati - N. Radovanovic (Belgrade, RS)

MONDAY, 21 MAY 2012 - 11:00 - 12:30

Room: Novi Sad

Neurohumoralna blokada u lečenju srčane insuficijencije: sartani i blokatori beta receptora u fokusu.

Chairpersons: M. Dilic (Sarajevo, BA), G. Milasinovic (Belgrade, RS)

- Dobrodošlica i uvod – P. Seferovic (Belgrade, RS)
- Blokada aktivacije neurohumoralnog sistema: osnov prevencije i lečenja srčane insuficijencije
D. Jakovljevic (Newcastle Upon Tyne, GB)
- Blokatori angiotenzina II: efikasni lekovi sa najmanje sporednih efekata u srčanoj insuficijenciji i hipertenziji
V. Mitrovic (Bad Nauheim, DE)
- Klinička efikasnost beta-adrenergičke blokade u srčanoj insuficijenciji i hipertenziji. (lecture in Russian)
V. Mareev (Moscow, RU)
- Umesto zaključka: Najvažnije poruke za kliničku praksu – P. Seferovic (Belgrade, RS)

MONDAY, 21 MAY 2012 - 14:15 - 15:45

Složena klinička stanja u srčanoj insuficijenciji - prikazi bolesnika.

Room: Novi Sad

Chairpersons: V. Kanjuh (Belgrade, RS), S. Dimkovic (Belgrade, RS)

- Ishemijski cerebrovaskularni insult i srčana insuficijencija - V. Kostic (Belgrade, RS)
- Prevencija i lečenje bubrežne slabosti kod bolesnika sa srčanom insuficijencijom - V. Lezajic (Belgrade, RS)
- Srce i srčana slabost u autoimunim reumatskim bolestima - M. Matucci-Cerinic (Florence, IT)
- Srčana slabost u plućnoj hipertenziji: etiopatogenetski principi i novi pravci lečenja - M. Samarzija (Zagreb, HR)

TUESDAY, 22 MAY 2012 - 11:00 - 12:30

Lokalna sesija - sve najvažnije na kongresu!

Room: Novi Sad

Chairpersons: F. Kenda (Ljubljana, SI) - D. Milicic (Zagreb, HR)

- Bazične - D. Jakovljevic (Newcastle Upon Tyne, GB)
- Nega bolesnika - M. Lainscak (Golnik, SI)
- Dijagnostika, vizualizacione metode i patofiziologija - L. Jovovic (Belgrade, RS)
- Medikamentozna terapija - A.D. Ristic (Belgrade, RS)
- Pejsmejeri, defibrilatori i drugi implantabilni uređaji - S.U. Pavlovic (Belgrade, RS)

Scientific Programme

Be part of your Congress, participate actively in the Scientific Programme!

Abstract submission: 15 November 2011 - 14 January 2012

Abstract-based Sessions

Oral sessions

Young Investigators Award (YIA) Sessions - Basic Science and Clinical

A competition designed for abstract submitters / presenters 35 years old or under. Finalists will present their research in oral YIA sessions moderated by two chairpersons and a panel of experts to judge the presentations and determine a First Prize Winner (€1000) and two Runners-Up (€250). YIA abstract presenters will benefit from free registration to the congress.

Nursing Investigator Award (NIA) Session

Submitting the abstract under NIA will automatically entitle you to take part in the Nursing award competition. Selected finalists will present their findings in oral session moderated by two chairpersons and a panel of expert judges who will determine a First Prize Winner (€1000) and two Runners-Up (€250). NIA abstract presenters will benefit from free registration to the congress. There is no age limitation.

Oral Abstract Presentation - Basic Science and Clinical

New format in 2012, fast-paced and interactive! Flash presentations on the research highlights: Aim / Methods / Results, followed by discussions animated by two experts chairing the session.

Moderated Posters sessions

The content of abstracts considered to be of special interest will be displayed in the form of a poster in a dedicated Moderated Poster Area. Presenters will briefly discuss keypoints of their research with two moderators in front of an appreciative audience during official coffee breaks. Posters are available for consultation throughout the poster session

Posters sessions

These sessions provide a visual display of research highlights. This format allows a maximum of viewing time for the research and peer to peer interaction. A very popular platform where our community truly comes together to meet and exchange knowledge - Five half-day sessions are planned.

Clinical cases

A session dedicated to presentations of your clinical case. Submit your abstract under this category for an opportunity to share your experience and interact with your colleagues and peers.

HFA Grants Become your Heart Failure Association champion!

By submitting an abstract you may be eligible for one of the 30 HFA Grants distributed by the Heart Failure Association in cooperation with your national Heart Failure Society or Working Group!

Read the application...

Because science, research and great trials are always in the making

Late Breaking Clinical Trials

Late Breaking Research Trials

On-going Clinical Trials

Online application forms available on 1st February 2012

Additional information on the dedicated programmes available on the website.

Language

The official language of the Congress is English. All lectures and presentations will be held in English, except six marked local language sessions. No translation will be provided.

Patient Website



Congresses

Journal



The Heart Failure Association of the ESC is a non-profit professional organisation for:

Cardiologists, Internists, Physicians, General Practitioners, Basic Scientists,
Epidemiologists, Nurses, Industry Affiliates, Health Care Providers

Education

- Educational Training programmes
- On Line Education
- Research Fellowship
- Nurse Fellowship
- Patient website

Knowledge

- Workshops
- Scientific Papers
- Guidelines
- Committees
- Research
- Journal

Networking

- Annual Congress
- Winter Research Meeting
- National Societies
- Heart failure management centres
- Social media

GET INVOLVED!
JOIN THE HFA of the ESC

Membership benefits

- The HFA quarterly newsletter
- Reduced registration fee for HFA Congress
- Reduced subscription to the EJHF
- Voting for HFA Board
- Opportunity to join committees

CONTACT THE HFA

hfa@escardio.org

www.escardio.org/HFA

